NASDAQ · GDRX

GoodRx Holdings, Inc.

$3.05 +$0.09 (+3.04%) 1D After hours
Charting by TradingView

Key Metrics

$1.00B
Market cap
48.77×
P/E · TTM
$787.89M
Revenue · TTM
$20.56M
Net income
EPS · TTM $0.05
Dividend yield —
Free cash flow $165.81M
Beta · 1Y 1.57
EBITDA · TTM —
Gross margin —

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Mar 2
    The stock moved +16.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 2
  • Feb 26
    The stock moved -18.8% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 26

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$1.00B
Enterprise value$1.25B
Shares outstanding338.7M
52-wk range$1.77 – $5.81
Avg volume · 20D2.0M
Net cash −$251.71M
Book value / share$1.64
IndustryServices-Computer Processing & Data Preparation
ExchangeNASDAQ
About GoodRx Holdings, Inc.
IPO dateSep 23, 2020
Employees697

GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E48.77
P/S1.27
P/FCF6.05
EV/EBITDA—
EV/Sales1.59
Graham №$1.41

Profitability

Gross —
Operating 5.8%
Net 2.6%
FCF 21.0%
ROE / ROIC 3.1% · 2.4%

Financial Health

Current ratio1.47
Quick ratio—
Debt / equity0.78
Debt / EBITDA —
Net cash −$251.71M
Working capital$407.27M

Cash Flow · TTM

Operating CF $170.33M
Capex −$4.52M
Free cash flow $165.81M
Buybacks $129.04M
Dividends paid —
Shareholder yield 12.9%

Piotroski F-Score

5 / 9
Middling fundamentals · 5 of 9 signals passing

Altman Z-Score

0.2
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

$1.41 vs $3.05
Trades 2.2× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings